Publications | Page 123 | Pathology & Laboratory Medicine

Filter By Faculty

Filter by Principal Investigator

2020

Billett HH, Reyes-Gil M, Szymanski J, Ikemura K, Stahl LR, Lo Y, et al. Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality. Thromb Haemost. 2020;120(12):1691-1699.

Kasashima H, Duran A, Cid-Diaz T, Kudo Y, Diaz-Meco MT, Moscat J. An Orthotopic Implantation Mouse Model of Hepatocellular Carcinoma with Underlying Liver Steatosis. STAR Protoc. 2020;1(3):100185.

Matrai C, Motanagh S, Mirabelli S, Ma L, He B, Chapman-Davis E, et al. Molecular Profiles of Mixed Endometrial Carcinoma. Am J Surg Pathol. 2020;44(8):1104-1111.

Cantu MD, Towne WS, Emmons FN, Mostyka M, Borczuk A, Salvatore SP, et al. Clinical significance of blue-green neutrophil and monocyte cytoplasmic inclusions in SARS-CoV-2 positive critically ill patients. Br J Haematol. 2020;190(2):e89-e92.

Auguste A, Blanc-Durand F, Deloger M, Le Formal A, Bareja R, Wilkes DC, et al. Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond Mutations: A Comprehensive Genomic Analysis. Cells. 2020;9(6).

Kang Y, Marzuk PM, Safdieh JE, Falcone DJ, Choi AM. Weill Cornell Medicine. Acad Med. 2020;95(9S A Snapshot of Medical Student Education in the United States and Canada: Reports From 145 Schools):S371-S374.

Vossoughi S, Fischkoff K, DeSimone RA, Schwartz J. Blood stewardship: conservation and supply of blood components during the severe acute respiratory syndrome coronavirus 2 pandemic. Transfusion. 2020;60(9):2156-2158.

Scholze H, Stephenson RE, Reynolds R, Shah S, Puri R, Butler SD, et al. Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes. Blood Adv. 2020;4(20):5226-5231.

Galassi TV, Antman-Passig M, Yaari Z, Jessurun J, Schwartz RE, Heller DA. Long-term in vivo biocompatibility of single-walled carbon nanotubes. PLoS One. 2020;15(5):e0226791.

Chaekal O-, Scaradavou A, Frenet EM, Albano MS, Cushing M, Desai P, et al. Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response. Blood Adv. 2020;4(20):5146-5156.